A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population: A Danish nationwide cohort study

Hanan Amadid*, Pernille F. Rønn, Maria B.N. Dunbar, Jakob S. Knudsen, Bendix Carstensen, Frederik Persson, Marit E. Jørgensen

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review


Aim: To assess lipid-lowering drug (LLD) use patterns during 1996-2017 and examine lipid levels in relation to the use of LLDs and prevalent atherosclerotic cardiovascular disease (ASCVD). Methods: Using a nationwide diabetes register, 404 389 individuals with type 2 diabetes living in Denmark during 1996-2017 were identified. Individuals were followed from 1 January 1996 or date of type 2 diabetes diagnosis until date of emigration, death or 1 January 2017. Redemptions of prescribed LLDs were ascertained from the nationwide Register of Medicinal Products Statistics. Data on lipid levels were sourced from the National Laboratory Database since 2010. LLD coverage was calculated at any given time based on the redeemed amount and dose. Trends in lipid levels were estimated using an additive mixed-effect model. Low-density lipoprotein cholesterol (LDL-C) goal attainment was assessed based on recommended targets by the 2011, 2016 and 2019 guidelines for management of dyslipidaemias. Results: LLD use has decreased since 2012 and only 55% of those with type 2 diabetes were LLD users in 2017. A decline in levels of total cholesterol and LDL-C, and an increase in triglycerides, was observed during 2010-2017. Annual mean levels of LDL-C were lower among LLD users compared with non-users (in 2017: 1.84 vs. 2.57 mmol/L). A greater fraction of LLD users achieved the LDL-C goal of less than 1.8 mmol/L compared with non-users (in 2017: 51.7% and 19%, respectively). Among LLD users with prevalent ASCVD, 26.9% and 55% had, as recommended by current 2019 European guidelines, an LDL-C level of less than 1.4 mmol/L and less than 1.8 mmol/L, respectively, in 2017. Conclusions: LLD use and LDL-C levels are far from optimal in the Danish type 2 diabetes population and improvement in LLD use could reduce ASCVD events.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Issue number10
Pages (from-to)2354-2363
Publication statusPublished - Oct 2021

Bibliographical note

Publisher Copyright:
© 2021 John Wiley & Sons Ltd.


  • atherosclerotic cardiovascular disease
  • dyslipidaemia
  • lipid-lowering drugs
  • pharmaco-epidemiology
  • type 2 diabetes


Dive into the research topics of 'A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population: A Danish nationwide cohort study'. Together they form a unique fingerprint.

Cite this